MAGE-1 (268-282)

MAGE-1 (268-282) is a synthetic peptide corresponding to amino acids 268 through 282 of the Melanoma Antigen Gene-1 (MAGE-1) protein, a member of the cancer-testis antigen family. Characterized by its immunogenic sequence, this peptide is widely recognized in the context of tumor immunology and antigen presentation studies. Its defined structure and sequence specificity make it a valuable tool for dissecting immune recognition mechanisms, particularly those involving cytotoxic T lymphocyte (CTL) responses against melanoma and other MAGE-1-expressing tumors. The research significance of MAGE-1 (268-282) extends to fundamental investigations into antigen processing, T cell epitope mapping, and the development of peptide-based immunological assays.

Epitope Mapping: The peptide serves as a well-characterized epitope for the identification and analysis of T cell responses in various immunological models. Researchers utilize it to delineate the specific regions of the MAGE-1 protein recognized by T cell receptors, thereby enhancing the understanding of antigenic determinants involved in tumor-associated immune responses. This application is critical for mapping functional epitopes that drive effective immune recognition, providing insights into the molecular interactions between peptide antigens and the adaptive immune system.

Antigen Presentation Studies: MAGE-1 (268-282) is frequently employed in assays designed to evaluate the processing and presentation of tumor-associated antigens by major histocompatibility complex (MHC) molecules. By loading the peptide onto antigen-presenting cells, scientists can investigate the mechanisms underlying MHC class I-restricted presentation and the subsequent activation of cytotoxic T lymphocytes. This approach is instrumental in elucidating how tumor antigens are displayed to immune effector cells, supporting the development of targeted immunological interventions.

Immunogenicity Assessment: The defined sequence of this peptide enables precise evaluation of CTL activation in vitro, making it a preferred reagent for immunogenicity assays. Researchers can assess the functional capacity of T cells to recognize and respond to the peptide, which aids in characterizing the immunological landscape of tumor-bearing models or patient-derived samples. Such studies contribute to a deeper understanding of T cell repertoire diversity and the factors influencing antigen-specific immune activation.

Vaccine Research Models: In preclinical research settings, MAGE-1 (268-282) is used to develop and evaluate peptide-based vaccine formulations aimed at stimulating antigen-specific T cell responses. Its role as a model antigen allows for the systematic study of adjuvant effects, delivery systems, and immune potentiation strategies. By serving as a prototype epitope, it helps researchers optimize vaccine constructs and assess the immunological parameters necessary for robust cellular immunity.

Assay Development and Quality Control: The peptide provides a reliable standard for the calibration and validation of immunological assays, such as enzyme-linked immunospot (ELISpot), flow cytometry-based tetramer staining, and cytotoxicity assays. Its consistent performance supports assay reproducibility, enabling laboratories to benchmark T cell recognition and function across different experimental platforms. This utility is essential for ensuring the accuracy and comparability of immunological data in both basic and translational research contexts.

1. Proinsulin C-peptide and insulin: Limited pattern similarities of interest in inter-peptide interactions but no C-peptide effect on insulin and IGF-1 receptor signaling

2. Implications of ligand-receptor binding kinetics on GLP-1R signalling

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists